Market News

Analysts See $0.18 EPS for Corcept Therapeutics (CORT); Immunogen (IMGN) Shorts Lowered By 18.97%

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Immunogen Inc (NASDAQ:IMGN) had a decrease of 18.97% in short interest. IMGN’s SI was 11.05M shares in April as released by FINRA. Its down 18.97% from 13.64 million shares previously. With 4.63M avg volume, 2 days are for Immunogen Inc (NASDAQ:IMGN)’s short sellers to cover IMGN’s short positions. The stock increased 0.29% or $0.03 during the last trading session, reaching $10.27. About 1.61M shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 195.97% since April 21, 2017 and is uptrending. It has outperformed by 184.42% the S&P500.

Analysts expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to report $0.18 EPS on May, 7.They anticipate $0.14 EPS change or 350.00% from last quarter’s $0.04 EPS. CORT’s profit would be $20.67 million giving it 24.43 P/E if the $0.18 EPS is correct. After having $0.17 EPS previously, Corcept Therapeutics Incorporated’s analysts see 5.88% EPS growth. The stock decreased 3.19% or $0.58 during the last trading session, reaching $17.59. About 620,239 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 52.11% since April 21, 2017 and is uptrending. It has outperformed by 40.56% the S&P500.

Investors sentiment decreased to 1.49 in 2017 Q4. Its down 0.47, from 1.96 in 2017Q3. It dived, as 30 investors sold Corcept Therapeutics Incorporated shares while 42 reduced holdings. 40 funds opened positions while 67 raised stakes. 87.40 million shares or 21.46% more from 71.96 million shares in 2017Q3 were reported. Old Mutual Global Invsts (Uk) Limited reported 1.07M shares. Acadian Asset Llc holds 0.19% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 2.48M shares. Clarivest Asset Ltd holds 155,270 shares. Hillsdale Invest Management holds 0.26% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 90,300 shares. Tci Wealth Advisors Inc reported 0% stake. Tiaa Cref Investment Mngmt Llc has 0.01% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 475,858 shares. Texas Permanent School Fund has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Alps reported 26,212 shares. Goldman Sachs Grp Inc owns 677,232 shares or 0% of their US portfolio. Eidelman Virant Cap invested in 0.42% or 40,000 shares. Fincl Bank Of Montreal Can holds 78,310 shares. Arrowstreet Capital Partnership invested in 541,446 shares. Legal And General Grp Incorporated Public Lc reported 172,821 shares stake. Lpl Ltd Company holds 0% or 10,833 shares in its portfolio. Profund Advsrs Ltd Liability Corporation has invested 0.01% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Among 7 analysts covering Corcept Therapeutics (NASDAQ:CORT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 11 analyst reports since February 2, 2017 according to SRatingsIntel. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by FBR Capital on Tuesday, March 20. Seaport Global initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, April 13 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Friday, September 8. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Thursday, February 2 by Ladenburg Thalmann. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Friday, November 3 by Stifel Nicolaus. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Thursday, August 24 by Piper Jaffray. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Thursday, March 8 by FBR Capital. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, October 11 with “Buy” rating.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.02 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 16.91 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Since December 8, 2017, it had 1 insider buy, and 5 insider sales for $515,904 activity. FISHMAN ROBERT S sold 8,000 shares worth $132,774. $155,102 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was bought by GALA RENEE D.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.36 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Investors sentiment increased to 1.38 in Q4 2017. Its up 0.22, from 1.16 in 2017Q3. It improved, as 26 investors sold ImmunoGen, Inc. shares while 39 reduced holdings. 37 funds opened positions while 53 raised stakes. 101.53 million shares or 15.77% more from 87.70 million shares in 2017Q3 were reported. Mufg Americas Hldgs Corp has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Advisory Svcs Ntwk Limited Co holds 0.01% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 10,962 shares. Deutsche National Bank Ag stated it has 667,504 shares or 0% of all its holdings. 619,357 are held by Raymond James And Assoc. Gsa Cap Partners Ltd Liability Partnership has 0.11% invested in ImmunoGen, Inc. (NASDAQ:IMGN) for 270,434 shares. Ubs Asset Management Americas Incorporated has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Janney Montgomery Scott Ltd Limited Liability Company holds 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN) for 74,689 shares. Guggenheim Capital Llc invested in 0% or 268,889 shares. California Pub Employees Retirement System holds 197,132 shares. 18,236 are held by First Republic Investment Mngmt. Bb&T Secs Ltd Com holds 87,531 shares or 0.01% of its portfolio. Ubs Oconnor Llc invested 0.04% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Cornerstone Advsrs Inc owns 250 shares for 0% of their portfolio. Wellington Management Limited Liability Partnership stated it has 406,661 shares. Highbridge Cap Mngmt Ltd Liability Corporation accumulated 109,863 shares.

Among 9 analysts covering Immunogen (NASDAQ:IMGN), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Immunogen had 31 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, July 6 by RBC Capital Markets. The firm has “Buy” rating by Canaccord Genuity given on Thursday, February 1. As per Friday, September 8, the company rating was maintained by Jefferies. The stock has “Buy” rating by RBC Capital Markets on Thursday, February 8. On Tuesday, August 29 the stock rating was maintained by Cowen & Co with “Hold”. The firm earned “Buy” rating on Friday, November 3 by Canaccord Genuity. The company was maintained on Monday, June 26 by Jefferies. RBC Capital Markets maintained ImmunoGen, Inc. (NASDAQ:IMGN) rating on Monday, October 2. RBC Capital Markets has “Buy” rating and $12.0 target. As per Friday, April 6, the company rating was maintained by Cantor Fitzgerald. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) earned “Outperform” rating by RBC Capital Markets on Monday, July 27.

Since February 13, 2018, it had 0 insider buys, and 12 insider sales for $3.27 million activity. 25,000 ImmunoGen, Inc. (NASDAQ:IMGN) shares with value of $300,405 were sold by JUNIUS DANIEL M. Enyedy Mark J also sold $736,084 worth of ImmunoGen, Inc. (NASDAQ:IMGN) on Wednesday, February 21. $168,618 worth of stock was sold by BARROWS CRAIG on Wednesday, February 21. Another trade for 10,000 shares valued at $115,300 was sold by Johnston David Brannon. $129,211 worth of ImmunoGen, Inc. (NASDAQ:IMGN) was sold by Ryll Thomas. $188,540 worth of stock was sold by Berkenblit Anna on Wednesday, February 21. Another trade for 11,379 shares valued at $123,804 was sold by Wingrove Theresa.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *